Fietsen Wim De Glas

Buy Genocea Biosciences Stock GNCA Stock Price Today & News

gnca stock

The company said it gave notice to The Nasdaq Stock Market Inc. for its plans to voluntarily delist its common … Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. When you see GNCA stock appear in the results, tap it to open up the purchase screen.

gnca stock

If you require advice in relation to any financial matter you should consult an appropriate professional. Provides a general description of the business conducted by this company.

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately. You can practice and explore trading GNCAQ stock methods without spending real money on the virtual paper trading platform. You’ll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.8%. Investment products are not insured by the Federal Deposit Insurance Corporation (FDIC) or guaranteed by a bank,

and may decline in value. If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov.

Genocea Biosciences Stock Earnings

You can find your newly purchased GNCA stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. The Fund Sentiment Score (fka Ownership Accumulation Score) finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-factor quantitative model that identifies companies

with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners,

the changes in portfolio allocations in those owners

and other metrics.

Please declare your traffic by updating your user agent to include company specific information. Genocea Biosciences (GNCA) reported Q earnings per share (EPS) of -$0.22, missing estimates of -$0.18 by 23.46%. In the same quarter last year, Genocea Biosciences’s earnings per share (EPS) was -$0.18. Genocea Biosciences is expected to release next earnings on -, with an earnings per share (EPS) estimate of -$0.18. Genocea Biosciences Inc (GNCA) stock is unchanged 0.00% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator. Genocea Biosciences Inc. shares plummeted late Monday after the tiny Cambridge, Mass.-based biotech said it was shifting its drug development focus and cutting staff by 40%.

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors…

Commodity and historical index data provided by Pinnacle Data Corporation. Unless otherwise indicated, all data is delayed by 15 minutes. The information provided by StockCharts.com, Inc. is not investment advice. No content on the website shall be considered as a recommendation or solicitation for the purchase or sale of

securities, futures, or other financial products. All information and data on the website are for reference only

and no historical data shall be considered as the basis for predicting future trends. Margin trading involves interest charges and heightened risks, including the potential to lose more than

invested funds or the need to deposit additional collateral.

  • Genocea Biosciences Inc (GNCA) stock is unchanged 0.00% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.
  • Unless otherwise indicated, all data is delayed by 15 minutes.
  • Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).
  • Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat’s FREE daily newsletter.

Before trading on margin, customers are advised to

determine whether this type of trading is appropriate for them in light of their respective investment

objective, experience, risk tolerance and financial situation. Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of

using total institutional ownership, which is that a significant amount of assets under management are

invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call

ratio indicator more closely tracks the sentiment of actively-managed funds. Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission (SEC).

No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends. Investments in stocks, options, ETFs and other instruments are subject to risks, including possible loss of the

amount invested. The value of investments may fluctuate and as a result, clients may lose the value of their

investment. Past performance should not be viewed as an indicator of future results.

Two days ago, it warned the company that its stock price sitting below $1 per share for 30 consecutive business days was grounds for delisting. By using this site, you are agreeing to security monitoring and auditing. Find exchange traded funds (ETFs) whose sector aligns with the same commodity grouping as the symbol you are viewing.

Investor HG Vora sees the real glitter in the company’s parts, and could have plans to boost shareholder value. Also, filings on Prevail Therapeutics, Universal Stainless & Alloy, Seres Therapeutics, Tivity Health, Chaparr… Genocea Biosciences Inc. on Tuesday told investors it plans to shut down and lay off all remaining employees.

GNCA Company Calendar

There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat’s FREE daily newsletter. This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind.

Shares of Genocea Biosciences Inc. surged 101% in premarket trade Monday after the biotech announced promising data from an early-stage clinical trial of its lead drug candidate, a personalized cancer vaccine. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.

L&F of Korea obtains license from CAMX Power for its GEMX® advanced cathode material platform for Lithium – Benzinga

L&F of Korea obtains license from CAMX Power for its GEMX® advanced cathode material platform for Lithium.

Posted: Tue, 02 May 2023 16:53:00 GMT [source]

Analysis of these related ETFs and how they are trading may provide insight to this commodity. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. In addition to this, Genocea Biosciences has announced that it will be voluntarily delisting shares of https://business-oppurtunities.com/advancing-in-your-career-by-dr-jeffrey-magee/ from the Nasdaq Capital Market.

Cosmos Health Inc (COSM) Stock Declines -3.17% This Week; Should You Buy?

Trades in your Webull Advisors account are executed by Webull Financial LLC, a member of the Securities Investor Protection Corporation (SIPC). That means your assets are protected up to $500,000 in value, including $250,000 in any cash awaiting reinvestment. We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. 13D/G filings can be filed by

groups of investors (with one leading), whereas 13F filings cannot. This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present

them separately.

  • You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes.
  • Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
  • Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of

    using total institutional ownership, which is that a significant amount of assets under management are

    invested passively to track indices.

  • “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient’s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient’s tumor. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Options trading entails significant risk and is not appropriate for all investors.

About Genocea Biosciences Inc

An indication of interest to purchase securities involves no obligation or commitment of any kind. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. Stocks and ETFs.Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC.

Genocea Biosciences, Inc. (GNCA) Stock Top Line Results for GEN-004 Not Statistically Significant – Warrior Trading News

Genocea Biosciences, Inc. (GNCA) Stock Top Line Results for GEN-004 Not Statistically Significant.

Posted: Tue, 20 Oct 2015 07:00:00 GMT [source]

We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes.

Is Lipocine Inc (LPCN) Stock a Smart Investment Wednesday?

The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Securities and Exchange Commission (SEC) to effect this delisting on June 2. Information contained on this website is general in nature and has been prepared without any consideration of

customers’ investment objectives, financial situations or needs. Customers should consider the appropriateness

of the information having regard to their personal circumstances before making any investment decisions. Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Your request has been identified as part of a network of automated tools outside of the acceptable policy and will be managed until action is taken to declare your traffic.

All information provided “as is” for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. It’s worth noting that the decision to delist shares comes after a warning from the Nasdaq Listing Qualifications department.

gnca stock

If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that  InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Today’s news has GNCA stock seeing heavy trading with some 81 million shares on the move as of this writing. For comparison, the company’s daily average trading volume is closer to 3.5 million shares. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.